Zervimesine

Cognition Therapeutics (CGTX) announced a $30 million direct offering of 14.7 million common shares to two new institutional investors. Closing is expected around August 29, 2025. Proceeds will fund Phase 3 program preparation for zervimesine in neurodegenerative disorders, working capital, and general corporate purposes. Titan Partners Group acted as the sole placement agent. This secures funding to advance zervimesine to Phase 3 trials, however, the offering causes share dilution.